Filing Flows › Niagen Bioscience (NAGE) › Q1 2025
Niagen Bioscience (NAGE) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 7, 2025
Niagen Bioscience (NAGE) reported revenue of $30.5M for the first quarter 2025 (Q1 2025), +38% from a year earlier and +5% from the quarter before. Operating margin was 15.7%, net earnings $5.1M (16.6% of revenue).
Niagen Bioscience, Q1 2025: revenue $30.5M (+38% year over year), operating margin 15.7%, net earnings $5.1M, operating cash flow $7.9M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $30.5M | +5% | +38% |
| Gross profit | $19.3M | +6% | +44% |
| Operating profit | $4.8M | -33% | — |
| Net earnings | $5.1M | -29% | — |
| Operating cash flow | $7.9M | -8% | 27× |
What changed
Revenue was $30.5M in Q1 2025, up 38% year over year and up 5% from the previous quarter. Consumer Products segment was the largest line at 71% of revenue. Consumer Products segment added $4.2M year over year (up 24%), 50% of the total change.
Gross margin was 63.4%, up 2.7 points from a year earlier. Operating profit was $4.8M, a 15.7% margin (up 19.0 points year over year). Operating expenses grew 3% against revenue growth of 38%. The fastest-growing cost line was Sales & marketing (+20%). Net earnings were $5.1M. The effective tax rate was 3.2%.
Operating cash flow was $7.9M (up 2572% year over year), 156% of net earnings. Non-cash charges added back $195K of depreciation and amortization and $1.1M of share-based compensation. Working capital and other items added $1.6M.
Questions
What was Niagen Bioscience's revenue in the first quarter 2025?
Niagen Bioscience (NAGE) reported revenue of $30.5M for the first quarter 2025 (Q1 2025), +38% from a year earlier and +5% from the quarter before.
Was Niagen Bioscience profitable in the first quarter 2025?
Operating profit was $4.8M (15.7% of revenue) and net earnings $5.1M.
Source: Niagen Bioscience 10-Q on SEC EDGAR.